Sanjay Ganapathi retweeted
Article link here if desired:
academic.oup.com/eurheartj/a…
Sanjay Ganapathi retweeted
FFR is a surrogate for ischemia. Ischemia is a marker of adverse outcomes, not a cause. Revascularization of individuals with ischemia does not improve outcomes on OMT. Why do we still obsess over FFR and its derivatives?
Sanjay Ganapathi retweeted
13/15
We thank everyone who were part of this. Please share our work widely, so that the public/patients get what they truly deserve. High time to stop blindly following what pharmaceutical industry has been making doctors do what they do like sheep. Time to make changes.
Sanjay Ganapathi retweeted
1/15
Our important work, The Citizens Protein Project 2 that analysed "hospital/doctor" prescribed whey protein vs. nutraceutical/fitness industry marketed whey protein is now peer-reviewed and published. Please share with your doctor!
Full paper: journals.lww.com/md-journal/…
Sanjay Ganapathi retweeted
New @TheLancet Meta-Analysis by #NelsonWang @BrighamWomens HF Fellow
What is the expected BP lowering with various antihypertensive regimens?
Robust model derived from n=104,176 pts across 484 RCTs
Terrific user-friendly tool: bpmodel.org/
thelancet.com/journals/lance…
Sanjay Ganapathi retweeted
Congratulations to superstar @KeckMedicineUSC resident, now chief resident @ayeshasinghmd on her new paper in @JAHA_AHA . Stay tuned for more publications from her. Source: Journal of the American Heart Association share.google/Tp2b1C5qcsospE3…
Sanjay Ganapathi retweeted
abbott.mediaroom.com/2025-05…
How many devices are approved by the FDA based on small (n<110), open-label, single-arm, non-randomized trial?
Sanjay Ganapathi retweeted
This is the latest publication of ISCHEMIA investigators. PCI vs CABG. My opinions of the use or useless information it conveys. sciencedirect.com/science/ar…
Sanjay Ganapathi retweeted
The Ina-RHD Multicenter Study highlights the significant burden of rheumatic heart disease in Indonesia 🇮🇩, with late-stage presentation, high prevalence of AF ⚡, and suboptimal anticoagulation 💊
🔗 Read the full article: doi.org/10.1016/j.jacasi.202…
@JACCJournals
Sanjay Ganapathi retweeted
Emerging data suggests that one-size-fits-all troponin thresholds may miss the mark, especially in older adults. Read more in #EHJ.
doi.org/10.1093/eurheartj/eh…
#troponin #ischemic #cardiotwitter @ESC_Journals @escardio
Sanjay Ganapathi retweeted
The reason why NI trials use a combined efficacy and safety NACE outcome is because it is typically biased towards NI (outcomes going in opposite direction cancel each other out!). Journals should know better, yet they publish these substandard studies.
Sanjay Ganapathi retweeted
Engage the whole family and achieve weight reduction: a model for obesity risk reduction in LMIC. @antonystanley09 @AbrahamSBabu @gesjay @sctimst_tvm @AnnFamMed @worldheartfed @IBTNetwork @mkali_twindad @NITIAayog @PMOIndia annfammed.org/content/23/2/9…
Sanjay Ganapathi retweeted
Lifestyle modification: engage the whole family, reap maximum benefits! @sctimst_tvm @gesjay @antonystanley09 @AnnFamMed epaper.newindianexpress.com/…
Sanjay Ganapathi retweeted
The cost of Branded drugs for HF is several-fold higher than generic drugs available in Janaushadhi Kendra journals.lww.com/hfji/fullte…
@gesjay @JPNadda @PMOIndia @NITIAayog @MoHFW_INDIA @hfai20 @AyushmanNHA #HeartFailure #GenericDrugs #Janaushadhi #ayushmanbharatscheme
Sanjay Ganapathi retweeted
Percutaneous Left Atrial Appendage Closure for Stroke Prevention in Hypertrophic Cardiomyopathy Patients with Atrial Fibrillation
@EthanRowin
heartrhythmjournal.com/artic…
Sanjay Ganapathi retweeted
I will start another debate on left atrial appendage occlusion. This one in Hyde Park format at #HRS2024
I have 9 reasons why I am not convinced this procedure benefits patients. This is percutaneous closure. Surgical closure was shown effective (along with AC) in LAAOS3
1/
Sanjay Ganapathi retweeted
"...fewer events than anticipated in the surgery group..." is a strawman!
Why would one expect SAVR rate to be higher than TAVI in this cohort with 1/3rd sample with bicuspid AS?
If they had considered equivalent rates (10% for both TAVI & SAVR), N would have increased 4-fold!
Sanjay Ganapathi retweeted
NOTION-2 did not demonstrate the noninferiority of TAVI compared to surgery for the primary endpoint at 1 year. Due to fewer events than anticipated in the surgery group, the trial lost statistical power, resulting in widened confidence intervals that crossed both the noninferiority boundary and the line of identity.
This is the methodological situation where a noninferiority trial is termed "Inconclusive" because no result can be significantly excluded. We cannot say TAVI is noninferior, we can't say it is inferior, we can't say it is superior. Check mate.
That said, NOTION-2 remains valuable for descriptive purposes and inclusion in meta-analyses. Long-term results with increased event rates will provide additional insights on the comparison of TAVI and SAVR in younger, low-risk patients.
academic.oup.com/eurheartj/a…